BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28028222)

  • 1. Influenza A surface glycosylation and vaccine design.
    Wu CY; Lin CW; Tsai TI; Lee CD; Chuang HY; Chen JB; Tsai MH; Chen BR; Lo PW; Liu CP; Shivatare VS; Wong CH
    Proc Natl Acad Sci U S A; 2017 Jan; 114(2):280-285. PubMed ID: 28028222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM
    Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine.
    Katsura H; Iwatsuki-Horimoto K; Fukuyama S; Watanabe S; Sakabe S; Hatta Y; Murakami S; Shimojima M; Horimoto T; Kawaoka Y
    Vaccine; 2012 Sep; 30(42):6027-33. PubMed ID: 22867723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal delivery of a cDC1 targeted influenza vaccine with poly(I:C) enhances T cell responses and protects against influenza infection.
    Lysén A; Gudjonsson A; Tesfaye DY; Bobic S; Bern M; Bogen B; Fossum E
    Scand J Immunol; 2022 Mar; 95(3):e13128. PubMed ID: 34923667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.
    Kim YJ; Ko EJ; Kim MC; Lee YN; Kim KH; Jung YJ; Kang SM
    Biochem Biophys Res Commun; 2017 Nov; 493(1):393-398. PubMed ID: 28887040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation of the Hemagglutinin Protein of H5N1 Influenza Virus Increases Its Virulence in Mice by Exacerbating the Host Immune Response.
    Zhao D; Liang L; Wang S; Nakao T; Li Y; Liu L; Guan Y; Fukuyama S; Bu Z; Kawaoka Y; Chen H
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28100622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice.
    Nishi T; Sakoda Y; Okamatsu M; Kida H
    Arch Virol; 2014 Oct; 159(10):2567-74. PubMed ID: 24824346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
    Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
    Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Quest for a Truly Universal Influenza Vaccine.
    Jang YH; Seong BL
    Front Cell Infect Microbiol; 2019; 9():344. PubMed ID: 31649895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.
    Hütter J; Rödig JV; Höper D; Seeberger PH; Reichl U; Rapp E; Lepenies B
    J Immunol; 2013 Jan; 190(1):220-30. PubMed ID: 23225881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate.
    Venereo-Sanchez A; Gilbert R; Simoneau M; Caron A; Chahal P; Chen W; Ansorge S; Li X; Henry O; Kamen A
    Vaccine; 2016 Jun; 34(29):3371-80. PubMed ID: 27155499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
    Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
    Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies.
    Ramírez-Salinas GL; García-Machorro J; Rojas-Hernández S; Campos-Rodríguez R; de Oca AC; Gomez MM; Luciano R; Zimic M; Correa-Basurto J
    Arch Virol; 2020 Apr; 165(4):891-911. PubMed ID: 32060794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
    Rudraraju R; Mordant F; Subbarao K
    J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.
    Wong G; Qiu X; Ebihara H; Feldmann H; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S435-42. PubMed ID: 26022441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.